116 related articles for article (PubMed ID: 24809073)
1. Response to "Incidence and self-management of hand-foot syndrome in patients with colorectal cancer".
Llanos EB
Clin J Oncol Nurs; 2014 Apr; 18(2):143. PubMed ID: 24809073
[No Abstract] [Full Text] [Related]
2. Incidence and self-management of hand-foot syndrome in patients with colorectal cancer.
Zhao Y; Ding Y; Lu Y; Zhang J; Gu J; Li M
Clin J Oncol Nurs; 2013 Aug; 17(4):434-7. PubMed ID: 23899983
[TBL] [Abstract][Full Text] [Related]
3. Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
Almeida da Cruz L; Hoff PM; Ferrari CL; Riechelmann RS
Clin Colorectal Cancer; 2012 Mar; 11(1):82-4. PubMed ID: 21764392
[No Abstract] [Full Text] [Related]
4. [Hand-foot syndrome].
Asao T; Kaira K
Nihon Rinsho; 2015 Feb; 73 Suppl 2():454-7. PubMed ID: 25831802
[No Abstract] [Full Text] [Related]
5. Sorafenib-induced hand-foot syndrome.
Sioulas AD; Triantafyllou K
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):653-4. PubMed ID: 25956488
[No Abstract] [Full Text] [Related]
6. T-DM1-related carotenoderma and hand-foot syndrome.
Dholaria B; Srinivasan S
Lancet; 2015 Apr; 385(9977):1509-10. PubMed ID: 25933279
[No Abstract] [Full Text] [Related]
7. Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
Zhang L; Xing X; Meng F; Wang Y; Zhong D
J Gastroenterol Hepatol; 2018 Jan; 33(1):209-225. PubMed ID: 28608993
[TBL] [Abstract][Full Text] [Related]
8. Do you know this syndrome? Hand-foot syndrome.
Braghiroli CS; Ieiri R; Ocanha JP; Paschoalini RB; Miot HA
An Bras Dermatol; 2017; 92(1):131-133. PubMed ID: 28225974
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
Ohtsuka T
J Dermatol; 2012 Nov; 39(11):943-4. PubMed ID: 22257303
[No Abstract] [Full Text] [Related]
10. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management.
Miller KK; Gorcey L; McLellan BN
J Am Acad Dermatol; 2014 Oct; 71(4):787-94. PubMed ID: 24795111
[TBL] [Abstract][Full Text] [Related]
11. Palmar-plantar erythrodysesthesia.
Gupta A; Mehta A; Khanna S
BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359464
[No Abstract] [Full Text] [Related]
12. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
13. Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
Corazza M; Minghetti S; Borghi A; Virgili A; Ballardini P
Int J Dermatol; 2014 Mar; 53(3):e180-2. PubMed ID: 23621794
[No Abstract] [Full Text] [Related]
14. Better compliance with the guidelines on hand-foot syndrome in patients treated with capecitabine in colorectal and breast cancer as a result of nursing education.
Krzemieniecki K; Zygulska AL; Kucharz J; Stokłosa
Przegl Lek; 2016; 73(7):460-4. PubMed ID: 29676887
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-induced grade III hand-foot skin reaction with ulcerative dermatitis on scrotum, penis, and earlobe.
Sirka CS; Sahu K; Pradhan S; Rout AN
Indian J Dermatol Venereol Leprol; 2019; 85(6):623-626. PubMed ID: 31584016
[No Abstract] [Full Text] [Related]
16. Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer.
Murugan K; Ostwal V; Carvalho MD; D'souza A; Achrekar MS; Govindarajan S; Gupta S
Support Care Cancer; 2016 Jun; 24(6):2575-81. PubMed ID: 26715292
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel induced severe palmar plantar erythrodysesthesia.
Kharmoum S; Errihani H
Pan Afr Med J; 2018; 30():70. PubMed ID: 30344854
[No Abstract] [Full Text] [Related]
18. Chemotherapy and loss of fingerprint; problematic issue beyond the side effect.
Mumyakmaz A; Altundag K
J BUON; 2016; 21(6):1566-1567. PubMed ID: 28039728
[No Abstract] [Full Text] [Related]
19. Incidence and implications of chemotherapy related hand-foot syndrome.
Nikolaou V; Syrigos K; Saif MW
Expert Opin Drug Saf; 2016 Dec; 15(12):1625-1633. PubMed ID: 27718746
[TBL] [Abstract][Full Text] [Related]
20. [Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations].
Burbach GJ; Zuberbier T
Urologe A; 2013 Nov; 52(11):1574-8. PubMed ID: 23744244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
